타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials | Inhaled corticosteroid (ICS, Inhaled corticosteroid, Inhaled corticosteroid (ICS) therapy) Sanofi·Asthma 243 trials | ||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Tezspire (tezepelumab) | AIN457 (secukinumab) | Inhaled corticosteroid (ICS) therapy |
Overview Company | Sanofi / Regeneron | AstraZeneca / Amgen | Novartis | Sanofi |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | TSLP (thymic stromal lymphopoietin) | Psoriatic Arthritis | Asthma |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps | Asthma | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Non-inflammatory structural airway disease does not respond to cytokine blockade. | — | — |
Positioning Development positioning | — | Add-on maintenance | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | , comparative clinical efficacy, prescribing patterns, safety outcomes, and future directions for individualized therapy |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. | biomarkers and optimize therapeutic strategies | Biomarkers |
Toxicology Species | Mouse | Cynomolgus monkey | — | — |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | — | — |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tezepelumab (Tezspire, AMG 157, MEDI9929, tezepelumab-ekko) AstraZeneca / Amgen·TSLP (thymic stromal lymphopoietin… 47 trials | Inhaled corticosteroid (ICS, Inhaled corticosteroid, Inhaled corticosteroid (ICS) therapy) Sanofi·Asthma 243 trials | ||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Tezspire (tezepelumab) | AIN457 (secukinumab) | Inhaled corticosteroid (ICS) therapy |
Overview Company | Sanofi / Regeneron | AstraZeneca / Amgen | Novartis | Sanofi |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | TSLP (thymic stromal lymphopoietin) | Psoriatic Arthritis | Asthma |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Severe asthma add-on maintenance, chronic rhinosinusitis with nasal polyps | Asthma | Asthma |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational | Investigational |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | Acting upstream of IL-4/IL-5/IL-13 covers both eosinophilic and low-eosinophil asthma, unlike downstream type-2 blockers. | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Non-inflammatory structural airway disease does not respond to cytokine blockade. | — | — |
Positioning Development positioning | — | Add-on maintenance | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Neutralizes epithelial-derived TSLP, blocking the alarmin signal that initiates dendritic-cell and ILC2 activation and downstream type-2 and non-type-2 airway inflammation. | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway | , comparative clinical efficacy, prescribing patterns, safety outcomes, and future directions for individualized therapy |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | Blood eosinophils, FeNO, total IgE fall on treatment but none is required for eligibility. | biomarkers and optimize therapeutic strategies | Biomarkers |
Toxicology Species | Mouse | Cynomolgus monkey | — | — |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | — | — |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Generally well tolerated — pharyngitis, arthralgia, back pain, and injection-site reactions. Hypersensitivity occurs rarely; live vaccines should be considered before starting. | — | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교